Eren Bali

One of my proudest moments as an investor occurred today as Alaffia Health announced its series A because it shows how the Aperture® Venture Capital vision of multi-level, multi-generational #impactinvesting is succeeding in the marketplace. Here’s the model in its most basic form : ✅As diverse fund managers with meaningful capital to allocate, we are changing the VC landscape every day just by doing our day jobs. ✅As Black/Brown investors with ~40 years experience collectively, Aperture GPs have access to talent /excellence that others do not, so our portfolio *organically* is more inclusive by race, gender and geography even while optimizing for financial outcomes (all about the alpha). ✅Our most successful portco’s are using financial #innovation to solve market problems that impact underrepresented demographics and underserved communities. Alaffia Health is a shining example of the impact portion of our overall fund thesis, and we couldn’t be prouder of TJ Ademiluyi and Adun Akanni, MPH, PMP - the dynamic brother-sister founder duo whose vision we have steadfastly supported on their journey. Congratulations to TJ and Adun from William Crowder and myself, as well as the whole Aperture team- Marjorie King Philip McKenzie Yves Louis-Jacques Tanvi Lal Michelle Dhansinghani Lisha Bell Katie Kelly Amy Chung Cindy Chong, CFA Brian Fernandes-Halloran Monroe France Jayden Pantel Darren Herman Evan Wladis Neal Triplett Thomas Scriven Peter Ammon Irina Bit-Babik Tim Milanich Rob Rahbari

37

18 Comments

🔍 𝐅𝐢𝐧𝐝𝐢𝐧𝐠 𝐏𝐫𝐨𝐝𝐮𝐜𝐭-𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐢𝐭: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐒𝐞𝐪𝐮𝐨𝐢𝐚'𝐬 𝐉𝐞𝐬𝐬 𝐋𝐞𝐞 🔍 Sequoia's Jess Lee on identifying product-market fit for early-stage startups: - Understand customers' needs deeply. - Iterate based on feedback. - Solve real problems. - Observe user engagement. - True product-market fit: Consistent user returns and recommendations. #StartupSuccess #ProductMarketFit #Entrepreneurship #CustomerFeedback #Innovation #Sequoia

5

Solve for information asymmetries! Architecture & Civil Engineering - Layout interpretation ~other industries: Healthcare - <Prescription> interpretation Financial Products - <Subject to market risks documentation> interpretation Loans - <Fine print> interpretation There’s going to be a slew of startups commercialising this year with a value prop of simplification using AI

5

I invested early in AI, recognizing its potential to improve how industries address major market challenges. And the companies I've backed personify AI’s impact: → Arcade helps teams streamline product demonstrations through content management and delivery. → Tennr (YC W23) enables healthcare practices of all sizes to optimize their back-office operations with enterprise quality automations. → Tonkean helps organizations achieve peak efficiency by using data to suggest ways to work productively and profitably. → SafelyYou saves lives by predicting when a fall risk is high, preventing incidents before they occur. The common denominator? AI has a real-world impact on each startup, whether that's: ✓ Uprooting inefficiencies ✓ Automating repetitive tasks ✓ Mitigating risks ✓ Making better decisions AI is the catalyst transforming industries, and startups that embrace it will come out on top.

95

7 Comments

🌟Innovative VC Firm Overcomes Exits Drought with Secondary Sales🌟 ⛵Navigating a challenging landscape where exits are scarce, Santa Barbara Venture Partners (SBVP) has pioneered a novel approach to sustain its growth and attract investors for its second fund: secondary sales. Instead of waiting for traditional exits like IPOs or acquisitions, SBVP opted to sell shares of its portfolio companies, demonstrating its ability to generate returns for investors and stand out in a competitive market. 🎤According to Dan Engel, founder and managing partner of SBVP, these secondary transactions have been a game-changer, sparking investor interest and bolstering the firm's credibility. By leveraging its recent successes, including a lucrative stake in sports-betting company DraftKings Inc.' acquisition of digital lottery app Jackpocket, SBVP seized the opportunity to return profits to its limited partners (LPs) and pave the way for its second fund. 💡Engel highlighted the challenges faced by young VC firms in raising subsequent funds, particularly amid a downturn in exit activity and heightened investor scrutiny. With traditional exit routes becoming increasingly elusive, the pressure is on for firms to demonstrate tangible returns and establish a track record of success. ✨"For us, secondary sales have been a game-changer. They've helped us return profits to our LPs and attract investors for our second fund," said Dan Engel. 💰For SBVP, the decision to pursue secondary sales was driven by the need to provide liquidity to LPs and validate its investment thesis in the eyes of prospective investors. By strategically offloading portions of its holdings in high-performing portfolio companies like Bark Technologies and Rad AI, SBVP not only generated substantial returns but also bolstered investor confidence in its ability to deliver results. ⚠Despite the complexities and potential stigma associated with early share sales, Engel emphasized the importance of prioritizing investor returns and seizing opportunities to unlock value for stakeholders. With a focus on profitability and transparency, SBVP remains committed to its mission of delivering sustainable growth and maximizing returns for its LPs. 🔍 "Returning profits to our investors is our top priority. By strategically selling shares, we're proving our commitment to delivering results and driving value for our stakeholders," added Engel. As SBVP continues to explore secondary transactions and expand its investor base, the firm stands as a testament to innovation and resilience in the face of market challenges. 🚀 ✅ Looking to raise capital for your #fund and increase the international pool of your LP #investors?   🤝 Need warm #LP introductions?   📝 Selling #secondaries to increase liquidity?   🧐 Looking for co-investments?   ▶ G+QUANT's link for inquiries and fund decks: https://lnkd.in/gjC_EuTE #VCInnovation #SecondarySalesSuccess #InvestorReturns #ValueCreation 

2

I used to spend 2-3 hours daily on clinic notes, skeptical of AI scribe technology. However, I've been impressed with RevMaxx, a generative AI company transforming clinical note creation by listening to physician-patient conversations and automatically generating comprehensive notes. This platform accurately captures crucial ICD-10 codes, saving valuable time ⏰. 👉 Why This Matters: - **Reducing Physician Burnout:** Administrative tasks are a significant contributor to physician burnout. Innovations like RevMaxx alleviate this burden effectively. #HealthcareInnovation #AI #PhysicianBurnout #MedicalDocumentation #HealthTech #RevMaxx

21

👩‍🔬 Ayble Health is building an end-to-end care platform for digestive health, utilizing technology like predictive AI to help more than 70M Americans who live with gut discomfort. 👨‍🔬 It's W6 / Q2 / 2024 & this week in our MGMT Boston startup series we’ve got Ayble Health, a Seed stage healthtech startup building a platform for digestive health, increasing access to nutrition and behavioral therapy for millions who live with gut discomfort to make care better, faster, and more personalized. Sam Jactel had a problem. He had lived with IBD (Inflammatory Bowel Disease) for 10 years. It even runs in his family. Lucky enough to have the privilege of incredible access to care, he was treated at Harvard training hospitals like Brigham & Women’s. But Sam never got the help he needed to use nutrition and psychology as tools to tackle his condition. He would go to the doctor, take drugs, and was still sick. In and out of the hospital with flare ups frustrated by this Grand Canyon wide gap in care. Who was treating the whole patient? And where? There are not enough GI dieticians or psychologists to treat patients. Up to 40% of Americans' daily lives are being disrupted by digestive troubles and some 70M Americans suffer from GI diseases. There are 150 licensed GI psychologists nationwide... By comparison, it would be harder to get into ANY Ivy League university than see a GI psychologist. Like, 1000x harder to see a GI psychologist than get into Harvard statistically speaking. Are you starting to see the problem? What started as an Excel spreadsheet has now been transformed into an end-to-end care platform built to scale access to specialized nutrition and psychology therapy and make GI therapy better, faster, and more personalized. Using advanced nutrition techniques, powered by AI, their team helps patients find and remove trigger foods to live better lives. Their core differentiator? This stuff works. After years doing research backed by 14 clinical studies, they’re going commercial. The proof is in the 💩 , I mean pudding. 2023 was a critical year of validation as their first year “out in the wild”. They’re already working with multiple large state based health plans, 75% of the Top 10 academic medical centers in the country, and several F500 type employers. Next year they hope to widen access to 10s of millions. Sam & the team are hiring across the board, investing in core platform differentiators and wanting to be in every conversation related to GI with the patient at the center. Operators to Know: -Susan Aman, Director of Engineering -Lance Laughlin, Senior Software Engineer -Stefania Patinella, M.A., NBC-HWC, Founding Health Coach -Jessica Russo, Director of Customer Success & Partnerships If you're interested in learning more, including the key roles Ayble is hiring for, the full post is linked in the comments! And sign up for the newsletter to see who we bring you next week, will you?? #bostontech #startups #healthtech

57

2 Comments

The opioid crisis was a sad hallmark of my years working for the Baker Administration. In a time of extreme partisanship at the federal level, this was one area where public policy, civil discourse, and private enterprise seemed aligned and sufficiently motivated to find a solution. What we learned, however, is that dollars and access only go so far in combatting a disease that knows no so specific demographic. Instead, it's apparent that a battery of tools is needed to combat and prevent addiction--ranging from strong safety nets, to novel non-addictive pain therapies, and better technology. Introducing Marigold Health. Shrenik Jain, Ravi Shah, Tracey Cohen, MD, FASAM and team have built a proprietary NLP-based platform that--most significantly--improves the lives of those suffering from SUD/SMI. One customer we spoke with noted, "We needed a unique treatment intervention that had supportive research, fit into a CMS established model with a recognized service code, and that would provide positive clinical outcomes in an efficacious and fiscally responsible manner”. Another plainly said: "Marigold is our best hope to reach into the lives and help those who many have already given up on." Honored to join Bill Evans, Sean Day, and the entire syndicate in doing our part to scale a tool we believe will become essential in the fight against addiction. Marigold Health Innospark Ventures Rock Health KdT Ventures Matt Fates Lily Zarrella Venkat Srinivasan

49

1 Comment

Want a front-row seat to the frontier of tech? We’ve got the role (or two) for you! We’re expanding our frontier-tech team at Blackbird by hiring a Frontier Tech Investments Associate and Foundry Fellows! Got questions? We've got answers... 1️⃣ What are the roles? 🧪 Associate = a full-time VC investment gig in our Blackbird Investments team, working directly with me. We’re looking for someone with a science and/or engineering background and more curiosity than they can handle. You’ll grow your own investment brand and practice, support our portfolio founders, and will help build Foundry, our early-stage frontier-tech accelerator. ✨ Foundry Fellow = a casual/contract gig in our Blackbird Investments team, ~15h per week for 3 months. The Fellowship is ideal for PhD students and ECRs who want to learn more about startups and VC. You’ll go deep on emerging areas relevant to your expertise (or curiosity!), get a front-row seat to groundbreaking companies in those areas, build out your non-academic network, and develop a solid writing practice. 2️⃣ Why are you hiring? We love frontier tech, and we’re ready to grow our team. 3️⃣ Wow, it’s so great that you’re starting to look at deep tech! Look, we get it: we don’t make a lot of noise about our frontier tech investing. Buuuut we’ve been deep-tech investors since we backed Tim Kentley-Klay to found Zoox back in 2014—we’ve been on incredible journeys with PsiQuantum (building the world's first utility-scale quantum computer right here in Australia!), Inventia Life Science (transforming drug discovery with high-fidelity cell models), Remedy Robotics (surgical robots for remote endovascular procedures), Opto Biosystems (minimally-invasive neural implants to treat cancer), and more. We believe that frontier technologies, and great frontier-tech investing, will be part of the solutions to the greatest problems humanity faces today. 4️⃣ When do applications close? May 31st at 11:59pm AEST. 5️⃣ I have more questions! I’m sure you do! Clare Birch and I are hosting an AMA to answer any and all questions about these roles. Want to know what a week in the life of our team looks like? What’s keeping us up at night? What our ideal candidate looks like? Come along and find out - registration link in the comments 👇 Apply for these roles: Associate - https://lnkd.in/gCfj4EUJ Foundry Fellowships - https://lnkd.in/gj6ATZVZ If you know anyone that we should meet, send me their details! Cameron Elise Ben Andrew Robin Joseph Adelaide James Olivia Lucinda Raghav Jesse Christie Mohamed Tom Amee Pablo Haya Loong Hon Joshua Benjamin Megan Harry Denzil Matthew Diana Daniel Tom Deanna Justin Amar Lilly Stone Thomas

114

4 Comments

Once you’re in it, you’re in it. #Startup #founders don’t just take financial risk - they invest years of their lives. For many, it’s absolutely worth it. To me, the first task is the most important one: to define your target and make absolutely sure it’s one worth that level of investment.

3

2 Comments

118 VCs (one hundred eighteen!) are gathering in San Diego next week - to meet with 30 SD startups. But it's so MUCH bigger than just those 30 co's. It brings VCs back - when they see quality companies. It helps those who are next-in-line and adjacent. It enables us to send deal flow all year 'round. It attracts talent and other companies. It inspires entrepreneurship. Connect is working for SD. Together, we're building the best damn innovation ecosystem on the planet. Year over year. Five.Ten.Thirty.

264

25 Comments

According to the latest report from Rock Health, digital health funding in Q1 2024 totaled $2.7B across 133 deals, with an average deal size of $20.6M. It doesn’t break out device-related investments, but most medtech founders I meet these days are being forced to chase tiny rounds made up of endless little checks, consuming valuable energy and slowing their progress. The benign neglect of this next generation of diagnostic and therapeutic devices is counterproductive and surprising. Given the crowded virtual care market, for example, I’d expect more such companies would be exploring medtech partnerships, investments or acquisitions that'd enable them to back integrate into delivering sharper, and more differentiated, care and treatment. This is exactly what Maverix Medical is doing from the other direction: Reshaping the entire spectrum of lung cancer care by integrating more advanced + effective approaches to screening and diagnosis, treatment and therapeutics, and even palliative care…And putting it all to work through an innovative provider network. One notable investor exception is Y Combinator partner Surbhi Sarna who’s been backing great teams like Selera Medical (YC W24) doing foundational work on ambitious medical devices. Without more support from investors like her, we’re going to increasingly find ourselves stuck with the incremental portfolio improvements from the incumbents, and that’s just not nearly enough.

58

5 Comments

Someone broke down the estimated costs of a $15 Sweetgreen salad. We need these cost graphics for digital health to help future founders. Especially for tech enabled cos, the greatest cost is labor. Much of the "value created" is in curation and matching, which means the gross margins are reliant on labor arbitrage. Pay someone $X, but get paid $X+Y% per visit. The challenge with healthcare is that you often have to pick one of two business models: 1. specialized, low volume, high cost, low gross margin % 2. generalized, high volume, low cost, high gross margin % I'd argue founders should focus on gross dollars over the lifetime of the customer (like Jeff Bezos said) instead of gross margin %'s, but we'll leave that for another time. The challenge is that many tech enabled digital health cos have high cost of goods sold (labor) and moderately high product, design, and engineering budgets. We must build differentiated solutions for patients, clinicians, and clients to be out incumbents, however, we're realizing that companies are ultimately valued on the discounted value of future cash flows. And the high SG&A costs at most organizations might be inbalanced to the unit economics of the business. I'm not sure the math pencils out for everyone unfortunately. But I'm just a guy on the internet, would love to hear the thoughts from those smarter than I (you!). Comment below. --- p.s. I have no idea the accuracy of the graphic and not an investor in Sweetgreen. Cheers. Credit: David Crowther

113

27 Comments

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

3

3 Comments

🔥Tune In to the Latest Fireside Chat with a VC in Healthech🔥 What percentage of VCs are former founders? 30% maybe more? I'd think a fair amount, yet how *exactly* does that transition happen and what perspectives change *radically* afterwards? Sigvards Krongorns shared exactly that - his journey from PwC consultant to Healtech founder, to a VC shaping the future of Healthtech startups. What we talked about: ✨ Sigvards' transition from a PwC consultant to founder to a VC ✨ What steps are necessary to bring innovative medical devices from concept to market ✨ How being a founder can prepare you for a role in venture capital ✨ What strategies help navigate the regulatory landscape in healthtech startups ✨ The right way to engage with VCs for startup funding ✨ What future trends in venture capital and Healthtech look like #HealthTech #VentureCapital #Innovation #StartupJourney #HealthcareInnovation #Entrepreneurship #FiresideChat #VentureCapitalInsights Full conversation can be found here:

32

5 Comments

第3弾は、Y CombinatorのWebサイトで「Healthcare」で分類されている、メンタルヘルス×モニタリング（1社）、企業の医療費削減（1社）、在宅介護支援（1社）、カップル向けAI恋愛アプリ（1社）について、スタートアップについてそれぞれまとめました。ぜひnoteをご覧ください。 ブログ記事はこちら（Here is the blog post）↓ https://lnkd.in/gT-RcVVJ *Although the articles are in Japanese, please feel free to contact me in English if you are interested in the content. I would like to introduce companies from the Y Combinator Winter 2024 Batch. Part 3 summarizes each of the startups categorized under "Healthcare": One in Mental health x monitoring, One in Reducing corporate healthcare costs, one in Home care support, and one in AI relationship app for couples.

8